Aim: The purpose of this study is to explore the levels of calprotectin in the serum of patients diagnosed with chronic rhinosinusitis (CRS) and to discover whether or not calprotectin might serve as a possible molecular proinflammatory biomarker for CRS. Materials and methods: The volunteers were separated into the following categories: The first group was made up of patients who were diagnosed with CRS and found to have nasal polyps on endoscopic nasal examination (CRSw NP); the second group was made up of patients who were diagnosed with chronic rhinosinusitis without nasal polyps (CRSwoNP); and the third group was made up of healthy controls. Participants' medical records, age, gender, smoking status, presence of asthma, aspirin-induced respiratory status, and Samter's triad were documented, as well as the demographic and clinical information that was acquired from them. The Nasal Obstruction Symptom Evaluation (NOSE) scale was verbally delivered to the participants. Results: The group that received CRSwNP had a mean serum calprotectin value of 80.14±7.58 ng/ml, whereas the group that received CRSwoNP had a value of 72.58±5.85 ng/ml, and the control group had a value of 62.14±6.36 ng/ml. There were six patients in the CRSwNP group who were found to have Samter's triad. The patients who had Samter's triad had a mean calprotectin value of 89.85±6.37 ng/ml, whereas the other patients in the CRSwNP group had a mean calprotectin value of 77.88±7.19 ng/ml. The mean levels of calprotectin in smokers and non-smokers did not vary significantly from one another (p = 0.33). The mean NOSE score was determined to be 76.11±3.96 in the CRSwNP group, 64.18±3.69 in the CRS wo NP group, and 33.48±5.01 in the control group, respectively. In addition to this, there was found to be a substantial positive association between the NOSE scores and the calprotectin levels of the subjects (<0.001) Conclusion: In conclusion, we found that instances of CRS were associated with an increase in the value of serum calprotectin, and there was a correlation between the value of serum calprotectin and the severity of CRS symptoms.